Boehringer Sheds US Pet Vaccines In $885M Elanco Deal
Eli Lilly and Co.'s animal health subsidiary agreed Wednesday to purchase Boehringer Ingelheim Vetmedica Inc.'s U.S. feline, canine and rabies vaccine portfolio in an $885 million deal that is part of...To view the full article, register now.
Already a subscriber? Click here to view full article